miRNEST database: an integrative approach in microRNA search and annotation

December 8, 2011

Despite accumulating data on animal and plant microRNAs and their functions, existing public miRNA resources usually collect miRNAs from a very limited number of species. A lot of microRNAs, including those from model organisms, remain undiscovered. As a result there is a continuous need to search for new microRNAs. Izabela Makałowska’s Laboratory of Evolutionary Genomics [...]

Read the full article →

MicroRNA-Driven Developmental Remodeling in the Brain Distinguishes Humans from Other Primates

December 8, 2011

How the human brain and human cognitive abilities evolved in less than six million years has long puzzled scientists. A new study conducted by scientists in China and Germany, and published December 6 in the online, open-access journal PLoS Biology, now provides a possible explanation by showing that activity levels of genes in the human [...]

Read the full article →

Plasma Components Affect Accuracy of Circulating Cancer-Related MicroRNA Quantitation

December 7, 2011

New protocols improve detection of microRNAs for diagnosis Philadelphia, PA, — MicroRNAs (miRNAs) that regulate processes including fertilization, development, and aging show promise as biomarkers of disease. They can be collected from routinely collected fluids such as blood, saliva, and urine. However, a number of factors can interfere with the accuracy of miRNA tests. In [...]

Read the full article →

MiraDx Highlights Breakthrough Publication Describing a Marker for Resistance to Platinum Treatment in Ovarian Cancer

December 7, 2011

NEW HAVEN, Conn., Dec. 7, 2011 /PRNewswire/ – Mira Dx® today notes the publication of breakthrough research showing that the KRAS-variant acts as a biomarker of poor survival and worse response to treatment for patients with ovarian cancer(1). Ovarian cancer patients with the KRAS-variant are twice as likely to die of their ovarian cancer, and three times [...]

Read the full article →

OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response

December 5, 2011

IRVINE, Calif., Dec. 5, 2011 /PRNewswire/ — OvaGene Oncology Inc., a molecular diagnostics company specializing in the development and commercialization of personalized gene-based diagnostics for gynecologic cancer, announced today that it has completed a major Licensing and Collaboration Agreement with The Moffitt Cancer Center, the only National Cancer Institute (NCI) Comprehensive Cancer Center in Florida. [...]

Read the full article →

Tiny genetic variation can predict ovarian cancer outcome

December 5, 2011

Yale Cancer Center researchers have shown that a tiny genetic variation predicts chances of survival and response to treatment for patients with ovarian cancer. The findings, published in the journal Oncogene, provide new insights into the biology of a new class of cancer marker and suggest a genetic test may help guide the treatment of [...]

Read the full article →

MicroRNAs and Vascular(dys)function

November 28, 2011

Elsevier recently published a special issue of  “Vascular Pharmacology” covering microRNAs: MicroRNAs and Vascular(dys)function, edited by Costanza Emanueli. Volume 55, Issue 4, Pages e1-e4, 59-118 (October 2011) For more details see: http://www.sciencedirect.com/science/journal/15371891/55/4

Read the full article →

International Conference: The reciprocal interactions of signaling pathways and non-coding RNA

November 18, 2011

16-19 September 2012 Ascona Switzerland Organized by the Competence Center for Systems Physiology and Metabolic Diseases of ETH and University Zurich together with EMBO. The conference at the Centro Stefano Franscini in Ticino will connect researchers working on non-coding RNA such as microRNA or long non-coding RNA and cellular signaling pathways relevant in development, cancer, [...]

Read the full article →

Firefly BioWorks looking for beta-testers of new kit

November 18, 2011

Firefly BioWorks is a startup company introducing an innovative technology platform for multiplexed quantification of biomolecules. Their products offer simultaneous detection of many targets per sample with minimal hands-on time. The assay is designed to work on standard flow cytometers and takes 4 hours from experiment to data. The company is launching an Early Access [...]

Read the full article →

Regulus Therapeutics to Present New In Vivo Data for microRNA-21 in Kidney Fibrosis

November 8, 2011

-Regulus Scientists to Provide Update on Lead Therapeutic Program at American Society of Nephrology Meeting- LA JOLLA, Calif., Nov. 8, 2011 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced presentations on its preclinical programs for the treatment of fibrosis at the American Association [...]

Read the full article →

← Previous Entries

Next Entries →